Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220881 | 0.83 | HDAC3 (0.53) | ALDH1A1FAAHHDAC3HDAC4HDAC1 | |
| SCHEMBL27331722 | 0.80 | ALDH1A1 (0.45) | ALDH1A1FAAHMEN1KMT2AECE1 | |
| SCHEMBL14978924 | 0.80 | MEN1 (0.39) | TRPA1ALDH1A1FAAHHDAC3HDAC4 | |
| SCHEMBL12564384 | 0.79 | LMNA (0.43) | TRPA1ALDH1A1FAAHHDAC3HDAC4 | |
| SCHEMBL10866810 | 0.79 | HDAC3 (0.41) | TRPA1ALDH1A1FAAHHDAC3HDAC4 | |
| SCHEMBL13116105 | 0.78 | MEN1 (0.61) | ALDH1A1FAAHMEN1KMT2AECE1 | |
| SCHEMBL2032064 | 0.78 | ECE1 (0.58) | FAAHHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17488363 | 0.78 | KDM4E (0.50) | TRPA1ALDH1A1FAAHHDAC3HDAC4 | |
| SCHEMBL22345533 | 0.77 | TSHR (0.50) | ALDH1A1FAAHHDAC3HDAC4HDAC1 | |
| SCHEMBL19720093 | 0.76 | FAAH (0.48) | ALDH1A1FAAHMEN1KMT2ACASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175904-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-11123416-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20190117754-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160375117-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9474806-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9474806-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8492364-B2 | Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492364-B2 | Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375117-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, B3GAT3, OGT | TRPA1 4828/4885ALDH1A1 1819/4885FAAH 2687/4885 |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | TRPA1 4865/4885ALDH1A1 1870/4885FAAH 2510/4885 |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | TRPA1 4865/4885ALDH1A1 1870/4885FAAH 2510/4885 |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | FUT6, B3GAT3, OGT | TRPA1 4828/4885ALDH1A1 1819/4885FAAH 2687/4885 |
| US-11123416-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | FUT6, B3GAT3, OGT | TRPA1 4828/4885ALDH1A1 1819/4885FAAH 2687/4885 |
| US-20220175904-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, B3GAT3, OGT | TRPA1 4837/4885ALDH1A1 1758/4885FAAH 2792/4885 |
| US-20190117754-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | TRPA1 4865/4885ALDH1A1 1870/4885FAAH 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.